Driving research of Myalgic Encephalomyelitis / Chronic Fatigue Syndrome (ME / CFS),
Post Treatment Lyme Disease Syndrome (PTLDS), Fibromyalgia and Post COVID .

Studying CSF to further reveal
pathogenesis mechanisms in ME/CFS

  • Collection of CSF samples and complementary plasma from ME/CFS patients in parallel to other neurological disorders (MS, ALS, HSE, TBI, etc.). 
  • Over 380 patients critically ill COVID patients enrolled with blood, urine, plasma samples collected for all, and CSF for those with severe neurological onset early in the disease.
  • 1,100 proteins have been detected in CSF.
  • 150 metabolites have been detected in urine.
  • In parallel, plasma metabolomics data (NMR + LC-MS) have been analyzed and resulted in close to 1,500 metabolites or metabolic ratios.
  • These data are undergoing computational analysis at Harvard and coordination with blood cell pellet data at Harvard and Stanford.


  • Underlying pathological mechanisms of ME/CFS are to a large extent unknown, but the presence of autoantibodies, cytokine pattern deviations and the presentation of cognitive and autonomic nervous system related symptoms indicate the role of immunology and neuroinflammation in the pathogenesis of the disease. 
  • Studying cerebrospinal fluid (CSF) could specifically provide information of the pathological processes occurring in the central nervous system.


  • Collect CSF and plasma from ME/CFS patients.
  • Conduct in-house quantitative proteomics and metabolomics analysis.
  • Share data with collaborative groups that want to analyze the CSF more in detail.
  • Collect CSF and plasma from people with other neurological diseases (including Parkinson’s, Multiple Sclerosis, Alzheimer’s, Herpes Simplex Encephalopathy,  Neuro-covid etc) and compare to ME/CFS.